http://www.roche.com/en-gbInhouseThe latest investor updates from Roche http://www.roche.com/inv-update-2008-05-16b Fri, 16 May 2008 08:30:00 GMT Patients with breast or colorectal cancer, two of the world¿s most common cancers, can expect further treatment advances with Avastin (bevacizumab) and Herceptin (trastuzumab) following new data that is being presented at the 44th American Society of Clinical Oncology (ASCO) annual meeting in Chicago at the end of May. http://www.roche.com/inv-update-2008-05-16a Fri, 16 May 2008 08:00:00 GMT We kindly invite investors and analysts to participate in an event to present and discuss new phase IIb data and results on R1583 GLP-1 analogue presented during the 2008 ADA (American Diabetes Association) Annual Scientific Sessions. Further, Roche will provide an overall update on its franchise in diabetes and metabolism. http://www.roche.com/inv-update-2008-05-16 Fri, 16 May 2008 05:30:00 GMT Overview provided for studies to be presented at the 2008 American Society of Clinical Oncology Annual Meeting; and updated timing provided for ongoing study in early-stage colon cancer http://www.roche.com/inv-update-2008-05-09 Fri, 09 May 2008 06:00:00 GMT Roche announced today that Actemra (tocilizumab) can significantly inhibit structural damage to joints in patients with rheumatoid arthritis (RA), a critical measure of effectiveness of an RA treatment. Actemra also improved the patients` physical function after one year of therapy, leading to a better quality of life. http://www.roche.com/inv-update-2008-05-05 Mon, 05 May 2008 08:00:00 GMT We are pleased to invite you to our Analyst briefings to discuss data presented by Roche at the American Society of Clinical Oncology meeting (ASCO) in Chicago. http://www.roche.com/inv-update-2008-04-29 Tue, 29 Apr 2008 14:30:00 GMT Genentech and Biogen Idec announced today top-line results from a phase II/III clinical study of Rituxan in Systemic Lupus Erythematosus.